CANCER INCIDENCE AND MORTALITY IN DELAWARE, 2015-2019


Sumitha Nagarajan, MPH, Chronic Disease Epidemiologist
Delaware Cancer Registry, Division of Public Health
October 10, 2022

Overview

- I&M report 2015-2019
 - Similar to previous I&M reports in terms of reporting all-site cancer rates and information
 - O Notable updates:
 - Summary site-specific tables
 - Trend analysis via Joinpoint
 - U.S. rates calculated using U.S. Cancer Statistics data instead of SEER data
- Census tract-level analysis compendium
 - Includes all-site cancer incidence rates and maps

ALL-SITE CANCER INCIDENCE

All-site Cancer Incidence, Delaware, 2015-2019



- 29,671 cancer cases
 - o average of 5,934 per year
- By sex
 - o Male 51%
 - o Female 49%
- By race/ethnicity
 - Non-Hispanic White 77%
 - Non-Hispanic Black 17%
 - o Hispanic − 3%

All-Site Cancer Incidence, Delaware vs. U.S., 2015-2019

Delaware: 468.8 per 100,000 Statistically significantly higher than U.S. (449.2 per 100,000)

• Improved - 2015-2019 rank: 13th; 2014-2018 rank: 8th


Delaware males: 513.1 per 100,000 Statistically significantly higher than male U.S. (487.9 per 100,000)

• Improved - 2015-2019 rank: 11th; 2014-2018 rank: 9th


Delaware females: 436.8 per 100,000 Statistically significantly higher than U.S. (423.2 per 100,000)

• Improved - 2015-2019 rank: 13th; 2014-2018 rank: 10th


Age-Adjusted All-Site Cancer Incidence Rate Trend by Sex; U.S. and Delaware, 2005-2019



Age-Adjusted All-Site Cancer Incidence Rate Trend by Sex and Race/Ethnicity; Delaware, 2005-2019




Percent Distribution of Cancer Cases by Cancer Site, Delaware, 2015-2019



NOTABLE SITE-SPECIFIC CANCER DETAILS

Site-specific Age-adjusted Incidence Rates by Sex, Delaware, 2015-2019

New for I&M report: tables of rates by cancer site



October 2022

Delaware Cancer Incidence Rates per 100,000 population by site and gender, 2015-2019

	Male an	d Female			Male						Female			
Cancer Site	DE Rate (All races)	U.S. Rate (All races)	DE Cases (All Races, 2015-2019)	National Ranking (2015-2019)	Cancer Site	DE Rate (All races)	U.S. Rate (All races)	DE Cases (All Races, 2015-2019)	National Ranking (2015-2019)	Cancer Site		U.S. Rate (All races)	DE Cases (All Races, 2015-2019)	National Ranking (2015-2019)
All Sites	468.8	449.2	29,671	13th	All Sites	513.1	487.9	15,215	11th	All Sites	436.8	423.2	14,456	13th
Lung and Bronchus Colon and Rectum Melanoma of the Skin	61.7 37.1 28.9	37.6	4,127 2,284 1.788	17th 25th† 8th†	Prostate Lung and Bronchus Colon and Rectum	125.9 68.8 42.7	64.0	4,057 2,065 1,193	10th 20th 27th	Female Breast Lung and Bronchus Colon and Rectum	136.1 56.2 32.5	128.0 50.3 33.0	4,392 2,062 1.091	10th 15th 28th
Urinary Bladder	23.4		1,524	5th	Urinary Bladder	40.3		1,164	5th	Uterus	30.6	27.6	1,080	13th
Non-Hodgkin Lymphoma	18.5	19.0	1,153	25th+	Melanoma of the Skin	38.0	29.1	1,092	5th	Thyroid	23.5	20.3	613	12th
Kidney and Renal Pelvis	17.2	17.3	1,081	26th+	Kidney and Renal Pelvis	23.4	23.5	690	26th	Melanoma of the Skin	22.0	18.3	696	14th+
Thyroid	15.9	13.8	817	10th+	Non-Hodgkin Lymphoma	22.6	22.9	637	24th†	Non-Hodgkin Lymphoma	15.2	15.7	516	26th
Pancreas	14.1	13.2	922	6th†	Oral Cavity and Pharynx	19.7	18.2	586	13th+	Pancreas	12.5	11.6	446	6th†
Oral Cavity and Pharynx	12.5	12.0	795	18th+	Leukemia	16.7	17.9	462	32nd	Kidney and Renal Pelvis	11.8	12.0	391	26th+
Leukemia	12.3	14.1	743	40th+	Pancreas	16.1	15.1	476	8th†	Urinary Bladder	10.1	8.4	360	8th+
Liver/Intraheptic Bile Duct	8.2	8.6	565	23rd	Liver/Intraheptic Bile Duct	12.7	13.1	408	22nd	Ovary	9.7	10.4	325	35th+
Myeloma	7.0	7.0	455	17th+	Stomach	8.9	8.5	254	12th†	Leukemia	8.8	11.0	281	46th
Stomach	6.3	6.4	399	20th+	Esophagus	8.3	7.9	247	20th+	Cervix	7.7	7.7	203	21st+
Brain/Nervous System	6.1	6.4	347	38th+	Myeloma	8.0		237	34th†	Oral Cavity and Pharynx	6.3	6.5	209	37th
Esophagus	4.7	4.5	308	26th+	Thyroid	7.7		204	20th	Myeloma	6.1	5.7	218	13th
Larynx	3.2	3.1	210	22nd	Brain/Nervous System	7.2	7.6	190	37th	Brain/Nervous System	5.2	5.4	157	35th+
Hodgkin Lymphoma	2.8	2.6	133	11th+	Testis	5.2	5.7	116	39th+	Liver/Intraheptic Bile Duct	4.4	4.8	157	24th+
					Larynx	4.9	5.3	149	20th+	Stomach	4.2	4.6	145	22nd†
					Hodgkin Lymphoma	3.2	2.9	75	10th+	Hodgkin Lymphoma	2.4	2.3	58	14th+
										Esophagus	1.8	1.8	61	22nd†
										Larynx	1.7	1.2	61	7th+

Technical Notes: Rates are per 100,000 population and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Delaware cases include Delaware residents only at the time of diagnosis. Delaware rates are referenced as DE and U.S. references the United States.

Source: Delaware: Delaware Department of Health and Social Services, Division of Public Health, Delaware Cancer Registry, 2022.

United States: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program SEER*Stat Database: U.S. Cancer Statistics 2001–2019 Public Use Research Database, 2021 submission

National rankings were accessed using Centers for Disease Control and Prevention, U.S Cancer Statistics. Available at https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https://asa492F962Fwww.cdc.gov/92Fcancer962Fdataviz%2Findex.htm#/AtAGlance/

Suggested Citation: Delaware Cancer Registry. Age-Adjusted Cancer Incidence Rates, 2015-2019. Delaware Department of Health and Social Services, Division of Public Health, 2022

[†] One or more states tied with Delaware for listed rank

Site-specific Age-adjusted Incidence Rates by Race, Delaware, 2015-2019

New for I&M report: tables of rates by cancer site

DELAWARE HEALTH AND SOCIAL SERVICES
Division of Public Health
Comprehensive Cancer Control Program

October 2022

Delaware Cancer Incidence Rates per 100,000 population by site and race, 2015-2019

Non-l	Hispanic Wl	hite		Non-	Hispanic Blac	k		Hispanic			
Cancer Site	DE Rate (Both Sexes	U.S. Rate) (Both Sexes)	DE Cases (2015-2019)	Cancer Site	DE Rate (Both Sexes)	U.S. Rate (Both Sexes)	DE Cases (2015-2019)	Cancer Site	DE Rate (Both Sexes)	U.S. Rate (Both Sexes)	DE Cases (2015-2019)
All Sites	481.3	466.5	22,772	All Sites	448.5	453.5	4,987	All Sites	378.8	352.2	942
Breast ⁹	138.2	133.6	3,273	Prostate ^d	188.1	176	990	Breast [©]	101.9	99.2	141
Prostate ^d	107.3	103.5	2,694	Breast [®]	139.6	127.8	876	Prostate ^d	48.7	87.2	109
Lung and Bronchus	66.1	60.6	3,427	Lung and Bronchus	54.9	58.2	587	Colon and Rectum	38.5	33.7	92
Melanoma of the Skin	37.5	29.8	1,693	Colon and Rectum	39.7	43	425	Corpus and Uterus, NOS	30.6	25.5	39
Colon and Rectum	37.4	37.6	1,713	Corpus and Uterus, NOS ⁹	30.1	28.4	203	Lung and Bronchus	30	29.1	57
Corpus and Uterus, NOS ⁹	31.6	27.9	807	Kidney and Renal Pelvis	20.4	19.1	228	Non-Hodgkin Lymphoma	20.8	17.5	50
Urinary Bladder	25.5	21.9	1,302	Pancreas	17.5	16.2	183	Urinary Bladder	18.4	10.8	33
Non-Hodgkin Lymphoma	18.9	19.8	914	Non-Hodgkin Lymphoma	14.7	14.2	157	Thyroid	15.3	13.7	59
Kidney and Renal Pelvis	17.3	17.5	797	Urinary Bladder	14.6	11.5	151	Liver and Intrahepatic Bile Duct	14.6	13.8	32
Thyroid	17.3	14.7	592	Myeloma	12.8	14.3	144	Kidney and Renal Pelvis	14.5	17.5	35
Oral Cavity and Pharynx	14.1	13.3	661	Liver and Intrahepatic Bile Duct	11.3	10.7	139	Leukemia	14.2	11.3	45
Pancreas	13.6	13.2	695	Thyroid	10.1	8.5	109	Stomach	12.4	9.4	28
Leukemia	12.7	14.9	578	Leukemia	9.1	10.9	98	Pancreas	11.6	11.9	21
Ovary ⁹	10.7	10.7	264	Oral Cavity and Pharynx	8.1	8.7	87	Ovary [®]	-	10	-
Cervix Uteri [®]	8.2	7.2	142	Stomach	8	9.7	85	Oral Cavity and Pharynx	8.5	7.2	20
Liver and Intrahepatic Bile Duct	7.2	7.3	373	Cervix Uteri®	7.2	8.8	40	Brain and Other Nervous System	7.9	5.2	27
Testis ^d	7.1	7	96	Ovary ⁹	6.2	8.5	40	Myeloma	7.8	6.8	16
Brain and Other Nervous System	6.6	7.3	266	Brain and Other Nervous System	3.9	4.1	44	Cervix Uteri ⁹	_	9.7	_
Myeloma	5.7	6.1	288	Hodgkin Lymphoma	2.6	2.6	27	Melanoma of the Skin	_	4.7	_
Esophagus	5.6	5	277	Larynx	2.2	4	26	Larynx	_	2.2	_
Stomach	5.6	5.2	267	Esophagus	2	3.7	22	Hodgkin Lymphoma	-	2.3	-
Larynx	3.5	3.2	173	Melanoma of the Skin	-	1	-	Testis ^d	_	5.4	-
Hodgkin Lymphoma	3	2.8	89	Testis ^d		1.5	_	Esophagus	_	2.8	_

Technical Notes: Rates are per 100,000 population and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Delaware residents only at the time of diagnosis. Delaware rates are referenced as DE and U.S. references the United States.

Source: Delaware: Delaware Department of Health and Social Services, Division of Public Health, Delaware Cancer Registry, 2022.

United States: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program SEER*Stat Database: U.S. Cancer Statistics 2001–2019 Public Use Research Database, 2021 submission
National rankings were accessed using Centers for Disease Control and Prevention, U.S Cancer Statistics. Available at https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https:%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fdataviz%2Findex.htm#/AtaGlance/

Suggested Citation: Delaware Cancer Registry. Age-Adjusted Cancer Incidence Rates, 2015-2019. Delaware Department of Health and Social Services, Division of Public Health, 2022.

[&]amp; Rate includes only males

Q Rate includes only females

⁻ Rates and frequencies fewer than 16 are suppressed


Delaware Cancers Sites with Statistically Significant Differences from the U.S., 2015-2019

Delaware Incidence Rate Statistically Significantly	Higher or Lower						
Different from U.S.	Males and Females	Males	Females				
Lung and bronchus	Higher	Higher	Higher				
Melanoma	Higher	Higher	Higher				
Urinary bladder	Higher	Higher	*				
Thyroid	Higher	*	Higher				
Leukemia	Lower	*	Lower				
Larynx	*	*	Higher				
Prostate (male only)		Higher	*				
Female breast cancer		*	Higher				
Uterus		*	Higher				

^{*} no statistically significant difference

ALL-SITE CANCER MORTALITY

All-site Cancer Mortality, Delaware, 2015-2019



- 10,363 deaths from cancer
 - o average of 2,073 per year
- By sex
 - o Male 53%
 - o Female 47%
- By race/ethnicity
 - Non-Hispanic White 79%
 - Non-Hispanic Black 17%
 - Hispanic 2%

All-Site Cancer Mortality, Delaware vs. U.S., 2015-2019

Delaware: 160.8 per 100,000 Statistically significantly higher than U.S. (152.4 per 100,000)

• Unchanged - 2015-2019 rank: 15th; 2014-2018 rank: 15th


Delaware males: 192.1 per 100,000 Statistically significantly higher than male U.S. (181.4 per 100,000)

• Worsened - 2015-2019 rank: 14th; 2014-2018 rank: 18th


Delaware females: 137.4 per 100,000 Statistically significantly higher than U.S. (131.1 per 100,000)

• Improved - 2015-2019 rank: 17th; 2014-2018 rank: 15th


Age-Adjusted All-Site Cancer Mortality Rate Trend by Sex; U.S. and Delaware, 2005-2019



Age-Adjusted All-Site Cancer Mortality Rate Trend by Sex and Race/Ethnicity; Delaware, 2005-2019



Percent Distribution of Cancer Deaths by Cancer Site, Delaware, 2015-2019



NOTABLE SITE-SPECIFIC CANCER DETAILS

Site-specific Age-adjusted Mortality Rates by Sex, Delaware, 2015-2019

New for I&M report: tables of rates by cancer site



October 2022

	Male ar	d Female				Male					Fer	nale		
Cancer Site	DE Rate (All races)	U.S. Rate (All races)	DE Cases (All Races, 2015-2019)	• •	Cancer Site	DE Rate (All races)	U.S. Rate (All races)	DE Cases (All Races, 2015-2019)	National Ranking (2015-2019)	Cancer Site	DE Rate (All races)	U.S. Rate (All races)	DE Cases (All Races, 2015-2019)	National Ranking (2015-201
All Sites	160.8	152.4	10,362	15th	All Sites	192.1	181.4	5,498	14th	All Sites	137.4	131.1	4,864	17
Lung and Bronchus	40.9	36.7	2,691	. 15th	Lung and Bronchus	49.1	44.5			Lung and Bronchus	34.5	30.7	1,258	3 151
Colon and Rectum	13.0	13.4	820) 29th†	Prostate	17.0	18.9	467	47th	Female Breast	21.2	19.9	723	10th
Pancreas	12.1	11.1	793	5th†	Colon and Rectum	15.5	16.0	439	31st	Colon and Rectum	11.0	11.3	381	31st
Liver/Intraheptic Bile Duct	6.7		455		Pancreas	14.3			4th	Pancreas	10.4			
Leukemia	6.5		409		Liver/Intraheptic Bile Duct	10.1	9.7		12th+	Ovary	6.4			
Urinary Bladder	5.4	4.2	341	1st	Leukemia	9.6	8.1	263	3rd	Uterus	5.9	5.0	219	
Non-Hodgkin Lymphoma	5.4		340		Urinary Bladder	9.6			1st	Leukemia	4.2			
Brain/Nervous System	4.0	4.4	248		Non-Hodgkin Lymphoma	7.3	6.9		15th+	Non-Hodgkin Lymphoma	3.9			
Esophagus	3.9		252	29th†	Esophagus	7.0	6.8	206	28th+	Liver/Intraheptic Bile Duct	3.8			
Myeloma	3.9	3.2	246	i 2nd	Brain/Nervous System	5.4			31st+	Myeloma	3.4			
Kidney and Renal Pelvis	3.6	3.6	238	29th†	Kidney and Renal Pelvis	5.0	5.2		32nd†	Brain/Nervous System	2.8	3.6		
Stomach	3.0	2.9	188	15th†	Myeloma	4.5	4.0	126	9th†	Kidney and Renal Pelvis	2.4	2.2	94	21st
Melanoma of the Skin	2.7		168		Stomach	4.2			12th	Urinary Bladder	2.3			
Oral Cavity and Pharynx	2.4	2.5	157	33rd†	Oral Cavity and Pharynx	4.0	3.9	119	20th+	Cervix	2.3	3 2.2	? 71	18th
Larynx	1.2		83		Melanoma of the Skin	3.9			7th†	Stomach	2.1			
Thyroid	0.4		28		Larynx	2.0			8th†	Melanoma of the Skin	1.7			
Hodgkin Lymphoma	0.3	0.3	17	7th†	Hodgkin Lymphoma	-	0.4	_		Esophagus	1.3			
					Thyroid	-	0.5	-		Oral Cavity and Pharynx	1.1	l 1.4	38	3 44th
					Testis	-	0.3	-		Larynx	0.6	6 0.4	23	3 3r
										Thyroid	0.5	0.5	19) 8th
										Hodgkin Lymphoma	_	- 0.2	_	

Technical Notes: Rates are per 100,000 population and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Disease Tenth Revision (ICD-10) coding system. Delaware deaths include Delaware residents only at the time of death. Delaware rates are referenced as DE and U.S. references the United States.

Source: Delaware: Delaware Department of Health and Social Services, Division of Public Health, Delaware Health Statistics Center, 2022.

United States: Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2020)

National rankings were accessed using Centers for Disease Control and Prevention, U.S Cancer Statistics. Available at https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcancer%2Fdataviz%2Findex.htm#/AtAGlance/


Suggested Citation: Delaware Cancer Registry. Age-Adjusted Cancer Mortality Rates, 2015-2019. Delaware Department of Health and Social Services, Division of Public Health, 2022

⁻⁻ Rates based on fewer than 16 deaths are not individually calculated

One or more states tied with Delaware for listed rank

Site-specific Age-adjusted Mortality Rates by Race, Delaware, 2015-2019

New for I&M report: tables of rates by cancer site



October 2022

Delaware Cancer N	Nortality Rates	per 100,000 pop	ulation b	y site and	race, 2015-2019
-------------------	-----------------	-----------------	-----------	------------	-----------------

Non-H	ispanic White			Non-l	Hispanic Blac		Hispanic				
Cancer Site	DE Rate (Both Sexes)	U.S. Rate (Both Sexes)	DE Cases (2015-2019)	Cancer Site	DE Rate (Both Sexes)	U.S. Rate (Both Sexes)	DE Cases (2015-2019)	Cancer Site	DE Rate (Both Sexes)	U.S. Rate (Both Sexes)	DE Cases (2015-2019)
All Sites	163.5	157.1	8,195	All Sites	172.6	178.5	1,775	All Sites	116.6	110.0	243
Lung and Bronchus	43.0	39.8	2,216	Lung and Bronchus	39.8	39.2	408	Lung and Bronchus	18.8	16.2	37
Breast [®]	20.5	19.9	540	Prostate ^d	32.5	37.9	120	Prostate ^d	-	15.7	-
Prostate ^d	14.9	17.8	328	Breast [©]	27.5	28.0	163	Breast [®]	-	13.8	_
Colon and Rectum	13.2	13.3	638	Pancreas	15.2	13.7	156	Colon and Rectum	10.8	10.9	23
Pancreas	11.8	11.2	606	Colon and Rectum	14.9	18.1	151	Liver and Intrahepatic Bile Duct	10	9.3	22
Ovary [®]	6.9	6.9	186	Corpus and Uterus, NOS [®]	10.3	9.0	65	Non-Hodgkin Lymphoma	-	4.5	_
Leukemia	6.7	6.5	338	Liver and Intrahepatic Bile Duct	9.9	8.5	113	Pancreas	-	8.7	-
Liver and Intrahepatic Bile Duct	6.1	5.9	311	Myeloma	6.0	6.0	61	Stomach	6.7	4.9	16
Urinary Bladder	5.8	4.7	295	Ovary [®]	5.9	5.9	37	Myeloma	-	2.7	-
Non-Hodgkin Lymphoma	5.7	5.5	281	Leukemia	5.1	5.3	51	Leukemia	-	4.4	-
Corpus and Uterus, NOS ⁹	5.1	4.6	147	Stomach	4.3	5.1	44	Corpus and Uterus, NOS ⁹	-	4.2	_
Brain and Other Nervous System	4.7	5.1	213	Urinary Bladder	4.2	3.4	39	Oral Cavity and Pharynx	-	1.5	-
Esophagus	4.5	4.4	222	Non-Hodgkin Lymphoma	3.5	4.0	37	Urinary Bladder	-	2.4	-
Kidney and Renal Pelvis	3.9	3.7	198	Kidney and Renal Pelvis	3.2	3.5	34	Brain and Other Nervous System	-	3.1	
Melanoma of the Skin	3.3	2.8	160	Cervix Uteri [®]	3.1	3.4	18	Kidney and Renal Pelvis	-	3.4	_
Myeloma	3.3	2.9	167	Brain and Other Nervous System	2.3	2.7	27	Larynx	-	0.6	-
Stomach	2.5	2.2	121	Oral Cavity and Pharynx	2.1	2.6	23	Esophagus	-	2.0	-
Cervix Uteri [®]	2.5	2.0	51	Esophagus	2.1	3.0	23	Melanoma of the Skin	-	0.7	-
Oral Cavity and Pharynx	2.4	2.7	119	Larynx	1.6	1.5	18	Cervix Uteri [©]	-	2.5	-
Larynx	1.2	0.9	60	Thyroid	-	0.5	-	Ovary [®]	-	5.0	_
Thyroid	0.5	0.5	25	Melanoma of the Skin	-	0.3	-	Hodgkin Lymphoma	-	0.3	_
Hodgkin Lymphoma	-	0.3	_	Testis ^d	-	0.1	-	Testis ^d	-	0.3	-
Testis ^d	-	0.3	_	Hodgkin Lymphoma	-	0.2	-	Thyroid	-	0.7	-

Technical Notes: Rates are per 100,000 population and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Diseas e Tenth Revision (ICD-10) coding system. Delaware deaths include Delaware residents only at the time of death. Delaware rates are referenced as DE and U.S. references the United States.

of Rate includes only males

Source: Delaware: Delaware Department of Health and Social Services, Division of Public Health, Delaware Health Statistics Center, 2022

United States: Surveillance, Epidemiology, and End Results (SEER) Program, SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2020)

National rankings were accessed using Centers for Disease Control and Prevention, U.S Cancer Statistics. Available at https://gis.cdc.gov/Cancer/USCS/?CDC_AA_refVal=https://s3A%2F%2Fwww.cdc.gov/%2Fcancer%2Fdataviz%2Findex.htm#/AtAGlance

Suggested Citation: Delaware Cancer Registry. Age-Adjusted Cancer Mortality Rates, 2015-2019. Delaware Department of Health and Social Services, Division of Public Health, 2022

Q Rate includes only females

⁻ Rates based on fewer than 16 deaths are not individually calculated

Delaware Cancers Sites with Statistically Significant Differences from the U.S., Males and Females, 2015-2019

Delaware Mortality Rate Statistically Significantly	Higher or Lower						
Different from U.S.	Males and Females	Males	Females				
Lung and bronchus	Higher	Higher	Higher				
Pancreas	Higher	*	*				
Urinary bladder	Higher	Higher	*				
Myeloma	Higher	*	Higher				
Melanoma	Higher	*	*				
Larynx	Higher	*	Higher				
Prostate (male only)		Lower	*				
Uterus (female only)		*	Higher				
Leukemia	*	Higher	*				

^{*} no statistically significant difference

Cancer Screening

- The Behavioral Risk Factor Survey (BRFS) collects information on cancer screening (data from 2020)
- Breast cancer Delaware ranks 17th nationally for mammography.
 - 73% of Delaware females 40 and older were screened for breast cancer in the previous 2 years compared to 72% nationally
- Colorectal cancer Delaware ranks 10th nationally for meeting USPSTF colorectal cancer screening.
 - 77% of Delawareans met the USPSTF recommendations compared to 74% nationally
- Prostate cancer Delaware ranks 15th for PSA tests.
 - 33% of Delaware males 40 and older has a PSA test in the past 2 years compared to 32% nationally
- Lung cancer No rank information since only five states participate in module
 - Of Delaware adults eligible for lung cancer screening, only 14.6% reported having a CT scan to screen for lung cancer

Cancer Prevention

 The Behavioral Risk Factor Survey (BRFS) collects information on cancer screening (data from 2020)

Tobacco use is the leading risk factor.

- In 2020, 15% of Delawareans were current smokers, almost the same as nationally (16%).
- Contributes to many cancers including lung, esophagus, kidney, urinary bladder, stomach, and pancreas

Overweight/Obesity

o In 2020, 69% of Delawareans 18 years of age and older were overweight or obese, compared to 67% nationally.

Physical Activity

 In 2019, 37% of adults 18 years of age and older did not meet aerobic or strengthening guidelines, same as nationally

Dietary Fruits and Vegetables

 In 2019, 14% of adults consumed five or more servings of fruits and/or vegetables a day, almost the same as nationally (13%)

Notable Demographic Disparities/Inequities

Breast cancer

• Non-Hispanic black women (27.5 deaths per 100,000 population) have a higher mortality rate for breast cancer compared to non-Hispanic white women (20.5 per 100,000).

Prostate cancer

• Non-Hispanic black men (32.5 deaths per 100,000 population) have a higher mortality rate for prostate cancer compared to non-Hispanic white men (14.9 per 100,000).

Colorectal cancer

- **Delaware males** (15.5 deaths per 100,000 population) have a higher age-adjusted mortality rate for colorectal cancer compared to Delaware females (11.0 deaths per 100,000 population).
- Non-Hispanic black (14.9 deaths per 100,000 population) have a higher mortality rate for colorectal cancer compared to non-Hispanic white (13.2 per 100,000) and Hispanic (10.8 per 100,000) Delawareans.

Lung cancer

- Delaware males (49.1 deaths per 100,000 population) have a higher age-adjusted mortality rate for lung and bronchus cancer compared to Delaware females (vs 34.5 deaths per 100,000 population).
- Non-Hispanic white (43.0 deaths per 100,000 population) have a higher mortality rate for lung cancer compared to non-Hispanic black (39.8 deaths per 100,000) and Hispanic (18.8 deaths per 100,000) Delawareans.

25

All DPH cancer reports can be found at:

http://dhss.delaware.gov/dph/dpc/cancer.html

For more information on cancer statistics from other states and the United States, visit CDC's data visualization tool:

https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/


Discussion/Wrap Up

Helen Arthur, MHA
Section Chief, Health Promotion and Disease Prevention
Division of Public Health

Today's Discussion

- Cancer I&M Reporting: Structure Change
- Cancer I&M Reporting: Partnerships in Data Research
- Screening For Life/Data Enhancement Project
- Strengthening Survivorship Expanding into Mental Health Clinics
- Future Request for Proposal (RFP) for Cancer Prevention and Control: Screening, Quality Improvement and Facilitation

Cancer I&M Reporting: Structure Changes




NCI/NAACCR Project

- Goal: Create sub-county zones (aggregated census-tracts), for sound reporting and yield more meaningful information on focus areas
- Progress: Currently reviewing zone possibilities with input from Epi Working Group (includes Epis across Division of Public Health)

I&M Report Changes

- Data briefs (2-3 pages) are planned following National Cancer Awareness month schedule
- Next release in October on prostate cancer (a month late), but a lung cancer data brief will be released in November
- Annual reporting will continue as presented today



Cancer I&M Reporting: Partnerships in Data Research

- Cancer Prevention and Control Integrations:
 - Increased collaboration among cancer program managers with increased data sharing
 - Delaware Cancer Registry data shared will be enhanced to help improve program planning and policy
 - Five-year state cancer plan
 - Build partnerships in the community for cancer research






Screening For Life/Data Enhancement Project

Centralized location for cancer program data

- Using Smartsheets for integration
- Collecting data on:
 - Patient Navigation/
 Screening for Life
 - Health Promotion
 Advocates/Health Care
 Connection
 - Delaware Cancer Treatment
 Program
- Standardized data reporting

Creating data dashboard for each program

 Holistic view of program data that can be easily shared



Source: Cancer Prevention and Control, Patient Navigation, Smartsheets, October 2022

Strengthening Survivorship by Expanding into Mental Health Clinics

CANCER SURVIVORSHIP IN DELAWARE

In 2019, more than 16.9 million cancer survivors lived in the U.S. By 2030, that number is projected to reach more than 22.1 million.

- American Cancer Society



ANXIETY AND DISTRESS

In long term cancer survivors, anxiety and distress are more common than in their peers who have never had cancer.

APPROACHES for Coping with Anxiety and Distress:

- Acceptance and Commitment Therapy (for fear of recurrence)
- Storytelling (help survivors and caregivers cope)
- Exercising together
- Telehealth (for rural areas)
- Resources
- Finding a silver lining

For more information on these approaches speak to your healthcare professional or

visit: https://www.cancer.gov/news-events/ cancer-currents-blog/2020/cancer-survivorsmanaging-anxiety-distress?cid=eb_govdel

There are a variety of programs available to cancer survivors in Delaware through Cancer Support Community Delaware.

The Cancer Support Community provides assistance in addressing the unique post-treatment needs of survivors including support groups, health coaching, educational workshops and mind-body stress reduction.

You can find contact information and more program details on the Cancer Support Community Delaware website here: https://cancersupportdelaware. org/, or by calling the location closest to you:

New Castle County
Wilmington: 302-995-2850

REMEMBER TO ASK YOUR DOCTOR IF YOU ARE UP-TO-DATE ON CANCER SCREENINGS!

- Breast all women age 50 74
- Cervical all women age 21 to 65
 Colorectal men and women age 50 to 75
- Lung men and women age 55 to 80, who meet certain criteria
- Prostate men age 50 and older, African-American men age 40 and older

CANCER RELATED FATIGLE

The most common side effect of cancer and cancer treatment is fatigue. What can you do?

- Talk with your healthcare provider
- Rest, but not too much
 Physical activity/exercise
- Cot or or other land
- Get enough sleep
- Plan/Prioritize activities
 Follow a healthy diet
- Stay socially active
- Manage anxiety and depression/emotional support

For more information speak to your healthcare professional or visit: https://www.cancer.org/ treatment/treatments-and-side-effects/physical-side-effects/fatigue/managing-cancer-related-fatigue.html

CANCER THRIVING AND SURVIVING SELF-MANAGEMENT PROGRAM

Free 6 week sessions for persons dealing with life after cancer. The program provides tools for living a healthier life.

- Small groups
- 2.5 hours per session
- 1 Session per week for 6 weeks


Goal: To provide individualized mental health counseling to cancer survivors and caregivers

Service: Six individualized therapy sessions per person, plan to serve 45 people in first year

Selection: Include providers who speak Spanish and or Haitian Creole, sensitive to LGBTQIA+, and offer telehealth and in-person therapy sessions

Future - Request for Proposal (RFP) for Cancer Prevention and Control: Screening, Quality Improvement and Facilitation

- Information will be available soon
- General information about any related RFP information will be shared with all CPC Bureau partners



Delaware Bids and Contracts: https://mmp.delaware.gov/

THANK YOU!